Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.08.

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th.

Insider Transactions at Roivant Sciences

In related news, CIO Mayukh Sukhatme sold 185,946 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the completion of the sale, the executive now directly owns 18,836,547 shares in the company, valued at $226,038,564. This represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eric Venker sold 177,704 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the sale, the chief operating officer now owns 740,976 shares of the company’s stock, valued at $8,550,863.04. The trade was a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,875,586 shares of company stock worth $21,491,661. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. US Bancorp DE increased its holdings in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the period. Natixis Advisors LLC grew its holdings in Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock worth $1,774,000 after acquiring an additional 11,726 shares during the period. Mutual of America Capital Management LLC grew its holdings in Roivant Sciences by 12.5% during the 3rd quarter. Mutual of America Capital Management LLC now owns 367,866 shares of the company’s stock worth $4,245,000 after acquiring an additional 40,787 shares during the period. Swiss National Bank grew its holdings in Roivant Sciences by 1.0% during the 3rd quarter. Swiss National Bank now owns 721,046 shares of the company’s stock worth $8,321,000 after acquiring an additional 6,900 shares during the period. Finally, Whalen Wealth Management Inc. acquired a new stake in Roivant Sciences during the 3rd quarter worth about $224,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Down 1.6 %

Shares of ROIV stock opened at $10.79 on Wednesday. The stock has a market cap of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.26. The stock has a 50 day simple moving average of $10.78 and a 200 day simple moving average of $11.46. Roivant Sciences has a 1 year low of $9.93 and a 1 year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts forecast that Roivant Sciences will post -0.92 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.